E-2,8-dimethyl-5-(3-phenylallyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 1166846-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: E-2,8-dimethyl-5-(3-phenylallyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 英文别名: 2,8-dimethyl-5-[(E)-3-phenylprop-2-enyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
• CAS: 1166846-98-5
• 化学式: C₂₂H₂₄N₂
• 分子量: 316.446
• InChiKey: KZVVSNNXOGHGRA-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  肉桂基氯 、 2,8-二甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Z-2,8-dimethyl-5-(3-phenylallyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 、 E-2,8-dimethyl-5-(3-phenylallyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  EP2236511

  摘要：

  公开号：

文献信息

• [EN] PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES<br/>[FR] PYRIDO[4,3-B]INDOLES CONTENANT DES FRAGMENTS RIGIDES
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2010051501A1

  公开（公告）日：2010-05-06

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及具有刚性基团的吡啶并[4,3-b]吲哚化合物。在一个实施例中，这些化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚化合物。在另一个实施例中，这些化合物是具有环烷基、环烯基或杂环基团的吡啶并[4,3-b]吲哚化合物。还提供了包括这些化合物的药物组合物，以及使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
  申请人：HUNG David T.

  公开号：US20100216814A1

  公开（公告）日：2010-08-26

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文揭示了具有刚性基团的吡啶并[4,3-b]吲哚。在一种实施例中，化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚。在另一种实施例中，化合物是具有环烷基，环烯基或杂环基团的吡啶并[4,3-b]吲哚。还提供了包括这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍，精神障碍，神经递质介导的障碍和/或神经元障碍。
• PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES
  申请人：Medivation Technologies, Inc.

  公开号：EP2346332A1

  公开（公告）日：2011-07-27
• LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110039825A1

  公开（公告）日：2011-02-17

  The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT 7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C 1 -C 4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C 1 -C 4 alkyl, CF 3 , CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH 2 ) m group, optionally substituted CH═CH group, optionally substituted CH 2 —CH═CH group, C≡C group, SO 2 group; n=1, 2; m=1, 2, 3; solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.
• US8906925B2
  申请人：——

  公开号：US8906925B2

  公开（公告）日：2014-12-09